APA

Smit J. V., de Jong E. M. G. J., van Hooijdonk C. A. E. M., Otero M. E., Boezeman J. B. M. & van de Kerkhof P. C. M. (20040928). Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin. : Journal of the American Academy of Dermatology.

Chicago

Smit Jürgen V, de Jong Elke M G J, van Hooijdonk Candida A E M, Otero Marisol E, Boezeman Jan B M and van de Kerkhof Peter C M. 20040928. Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin. : Journal of the American Academy of Dermatology.

Harvard

Smit J. V., de Jong E. M. G. J., van Hooijdonk C. A. E. M., Otero M. E., Boezeman J. B. M. and van de Kerkhof P. C. M. (20040928). Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin. : Journal of the American Academy of Dermatology.

MLA

Smit Jürgen V, de Jong Elke M G J, van Hooijdonk Candida A E M, Otero Marisol E, Boezeman Jan B M and van de Kerkhof Peter C M. Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin. : Journal of the American Academy of Dermatology. 20040928.